Press play above, or see the text transcript below.
Indoor Air Quality
Indoor air in our home and workplace can have dust, mold, smoke, chemicals, and radon.
What you can do:
Use and share these tips from the American Lung Association (ALA) and the US Consumer Product Safety Commission (CPSC) to improve indoor air quality.
- Open doors or windows for a brief time daily to vent spaces.
- Install carbon monoxide detectors.
- Change air filters often.
- Use a portable air cleaner.
- Remove sources of indoor smoke, like cigarettes.
- Have your home checked for radon. It is a naturally occurring, radioactive gas found in many areas around the US and is a leading cause of lung cancer. If your home has never been checked for radon, this should be done.
What SPIROMICS is doing:
There is a multi-center study launching to see if portable air cleaners can improve COPD health.
Indoor air pollution and lung function was the focus of a recent SPIROMICS publication.
[SPIROMICS logo on screen] SPIROMICS: SubPopulations and InteRmediate Outcome Measures in COPD Study
[SOURCE logo on screen] SOURCE: SPIROMICS Study of Early COPD Progression
Information sources:
Visit the ALA website for more on COPD and indoor air quality.
See the indoor air quality guide from the US Consumer Product Safety Commission.
This content was developed by the University of North Carolina at Chapel Hill, Collaborative Studies Coordinating Center, IRB #: 10-0048 (SPIROMICS) and 20-2236 (SOURCE). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
ACKNOWLEDGEMENTS: SPIROMICS is supported by NIH/NHLBI contracts (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C) and grants (U01 HL137880, U24 HL141762, R01 HL182622, and R01 HL144718). SOURCE is supported by NIH/NHLBI grant (R01 HL144718).
SPIROMICS and SOURCE are supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan/Viatris.
Music: “Hand in Hand” by Nicolai Heidlas